Should the federal government reschedule cannabis? Implications for marijuana use, research, policy

Quick Overview

Federal rescheduling of cannabis from Schedule I to Schedule III is extremely likely to be finalized soon via an administrative rule, which will immediately eliminate the punitive tax Section 280E for state-licensed businesses, although it will not automatically legalize sales or solve major issues like banking access or Food Drug and Cosmetic Act compliance.

Key Points: The rescheduling process, initiated under President Biden and resumed under President Trump, is currently held up only by a final procedural step, likely involving a hearing, with odds of completion deemed "extraordinarily high" by legal expert Rob Mikos. The primary immediate benefit of rescheduling to Schedule III is the automatic elimination of Internal Revenue Code Section 280E, which currently prevents cannabis companies from claiming ordinary tax deductions, a change that could lower consumer prices or increase worker wages. Dr. Peter Ginspoon, a clinician, notes that rescheduling signals government admission that cannabis is a medicine, contrasting its low documented harms against the high mortality rates of descheduled substances like tobacco and alcohol. Rescheduling does not automatically legalize cannabis sales, as Schedule III drugs still require DEA licensing, and the sale of marijuana remains in violation of the Food Drug and Cosmetic Act because HHS explicitly stated it is not approving marijuana as a drug. Ephetaya Harvey argues the move is "a dollar short and a day late," stating that rescheduling fails to address the racialized and class-based harms of the War on Drugs, such as disproportionate targeting of Black communities. Catalytic, though not immediate, effects of rescheduling include potential long-term improvements in banking access, state-level reform, federal policy shifts, and changes in the international landscape. Clinically, rescheduling may decrease stigma, potentially lower patient costs (as high costs currently force some off cannabis and back onto opiates), and improve research quality by allowing scientists access to more relevant cannabis products.